A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.

Also called NCT02973321

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 296 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02973321
  • EudraCT 2016-001328-77
Other papers using this trial's data
  • Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide Diabetes, obesity & metabolism, 2021-08 DOI, PubMed 33822469, PMC8359969 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Germany, Hungary, Mexico, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02973321. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-02 (actual); primary completion 2017-12-27 (actual). Results posted on 2021-02-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
SAR425899
Intervention (Drug)
Placebo
Intervention (Drug)
Liraglutide
Intervention (Drug)
Metformin
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct02973321
Content hash
47b8d929c3fc4355d1770cbd7fc4d95b12299962588b3ccec5ea0de88c1649ad